- Company
- Re-evaluation possibility of 'Bylvay' gathers attention
- by Eo, Yun-Ho May 26, 2025 05:57am
- Attention has been drawn to when 'Bylvay Cap,' the first medicine chosen for the 'Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations,' will be re-evaluated. Bylvay (odevixibat), Ipsen Korea's treatment option for progressive familial intrahepatic cholestasis (PFIC) in patients a
- Company
- Pfizer’s Lorviqua is granted reimbursement in Korea
- by Whang, byung-woo May 26, 2025 05:54am
- Lorviqua (lorlatinib), a treatment for ALK-mutated non-small cell lung cancer (NSCLC), has been approved for reimbursement as a first-line treatment, heralding a tectonic shift in the field. Experts saw this as a positive development in addressing unmet patient needs and improving access to treatment. In this sense, the presence of third-gene
- Company
- Accomplishments of the approval-drug price pilot project
- by Eo, Yun-Ho May 23, 2025 05:52am
- With the drugs that were reviewed for approval and drug prices simultaneously about to be commercialized, the industry gathers attention. The Ministry of Health and Welfare (MOHW) has been running the 'Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations' since 2023 to improve tre
- Company
- CKD-Novartis new drug advances to the next phase trial
- by Chon, Seung-Hyun May 23, 2025 05:52am
- Chong Kun Dang (CKD)'s new drug candidate out-licensed to Novartis is entering the next clinical stage. CKD has secured its first milestone payment of KRW 7 billion, 1 year and 6 months after the technology export contract. CKD announced on May 22 that it expects to receive a milestone payment of USD 5 million (KRW 7 billion) from Novartis
- Company
- Won-dollar rate lowest in 6mths... industry mixed
- by Kim, Jin-Gu May 23, 2025 05:51am
- With the won-dollar exchange rate falling below KRW 1,400, pharmaceutical and biotech companies are experiencing a mix of anticipation and concern. If the prolonged high exchange rate returns to previous levels, API imports and overseas clinical trial costs are expected to decrease, leading to an improvement in the cost structure. On the othe
- Company
- Will Tibsovo be reimbursed for cholangiocarcinoma this time?
- by Eo, Yun-Ho May 22, 2025 06:10am
- Attention is focused on whether the targeted anticancer drug “Tibsovo” for cholangiocarcinoma and acute myeloid leukemia will be successful in its attempt to be reimbursed by health insurance in Korea. Servier&160;Korea’s IDH1 (isocitrate dehydrogenase 1) genetic mutation targeting therapy recently passed the Health Insurance Review an
- Company
- SK Bioscience wins the '8-year Prevenar patent dispute'
- by Kim, Jin-Gu May 22, 2025 06:09am
- In a patent infringement trial against Pfizer involving SK Bioscience's export of 'SKYPneumo' raw solution, SK Bioscience has won after eight years. The latest ruling is expected to enable SK Bioscience's global export of its pneumococcal conjugate vaccine 'SKYPneumo' raw solution. Ruling that 'Exporting SK Bioscience's SKYPneumo ra
- Company
- KPBMA proposes policies ahead of the presidential election
- by Kim, Jin-Gu May 22, 2025 06:08am
- Ahead of South Korea's 21st presidential election, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has proposed "The Ten Pillars of Pharmaceutical and Biotechnology Policies." KPBMA's proposal can be summarized in three keywords: supporting R&D, establishing an AI-based new drug development platform, and improvi
- Company
- "Aiming the Alzheimer's market with ultrasound"
- by Whang, byung-woo May 22, 2025 06:07am
- Korea's biotech company Deepsonbio is gaining interest for its ultrasound-based brain disorder treatment technology. The company's recent exploratory clinical trials demonstrated the effect of improving cognitive function for patients with Alzheimer's disease and those with normal pressure hydrocephalus. Deepsonbio plans to enter the market
- Company
- Dyslipidemia drug 'Leqvio' enters drug price negotiatiation
- by Eo, Yun-Ho May 21, 2025 06:37am
- Leqvio, a new drug for dyslipidemia administered once yearly, has recently entered into negotiations with the National Health Insurance Service (NHIS). In February, Novartis Korea's siRNA drug Leqvio (inclisiran) had initially failed at setting criteria for 'reducing cardiovascular events in patients with atherosclerotic cardiovascular d
